Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 11, 2006 Brian Lawler	More Work on Cancer Drug for Genentech The FDA asks for more data about Avastin, which could be used to treat various cancers. Investors, take note.
The Motley Fool February 25, 2008 Brian Lawler	A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool December 6, 2007 Brian Lawler	Genentech Voted Down An FDA panel recommends against expanded use of Genentech's lead drug.
The Motley Fool June 2, 2009 Brian Orelli	Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool November 17, 2006 Brian Lawler	Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
The Motley Fool April 14, 2008 Brian Lawler	Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results.
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
The Motley Fool January 15, 2008 Brian Lawler	Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained.
The Motley Fool April 30, 2008 Brian Lawler	A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
BusinessWeek January 12, 2004	Arthur Levinson The scientist-turned-CEO plans to move Genentech into the pharmaceutical big leagues.
The Motley Fool November 17, 2008 Brian Orelli	The Little Chemotherapy That Could Abraxis BioScience has a lot of potential, but, in this market, the company is going to have to show investors that it can make it over the hill before they're going to jump on board.
The Motley Fool July 8, 2004 Charly Travers	Genentech's Next Billion-Dollar Drug The cancer drug Avastin looks like a big winner. The market had exceptionally high expectations for this product, and it certainly seems well on its way to becoming a blockbuster drug.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool November 21, 2008 Brian Orelli	The Comeback of the Century? AstraZeneca is trying to revive Iressa.
The Motley Fool August 27, 2007 Brian Lawler	Round 2 for Genentech Learn a lesson or two from Genentech's's dance with the FDA. The drugmaker's experience serves as a reminder of the fickle nature of the government agency, and the sometimes frustrating process of bringing a medication to market.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
The Motley Fool November 21, 2008 Brian Orelli	Coughing Is Bad for Amgen's Health Safety concerns halt drug trial, but all is not lost.
The Motley Fool August 14, 2008 Brian Lawler	Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool October 16, 2007 Brian Lawler	Genentech Fitting Better Cancer treatment Avastin continues to surge for the biopharma with a jump on the competition. Investors, take note.
The Motley Fool July 15, 2008 Brian Lawler	Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings?
BusinessWeek October 6, 2003 Arlene Weintraub	Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science."
The Motley Fool December 4, 2007 Brian Lawler	Will Avastin Squeeze Past the FDA? Unless an FDA advisory panel provides extremely strong reasoning for approving Avastin on the evidence of PFS benefits alone, Genentech and its investors should expect another approvable letter come January.
The Motley Fool September 23, 2009 Brian Orelli	Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer.
BusinessWeek July 31, 2006 Gene G. Marcial	Genentech Is More Robust Than It Looks Genentech, the world's second-largest biotech and an innovative developer of biotherapeutics, gets no favors from the Street.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
The Motley Fool November 29, 2011 Brian Orelli	Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.
The Motley Fool March 17, 2008 Brian Lawler	Genentech Takes Center Stage There might be more partnerships in store for this drugmaker.
The Motley Fool April 29, 2005 Tim Hanson	Genentech's Promising Future Cancer drug Avastin is finding new uses. How will outside forces affect its potential? Investors take note.
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
Chemistry World June 12, 2012 Nina Notman	Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer.
The Motley Fool June 4, 2008 Brian Lawler	Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares.
The Motley Fool March 13, 2009 Brian Orelli	Pfizer Finally Gets a Hit! Positive results on Pfizer's cancer drug Sutent come earlier than expected.
The Motley Fool July 12, 2006 Stephen D. Simpson	Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.
The Motley Fool January 22, 2010 Brian Orelli	Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line.
The Motley Fool June 21, 2011 Brian Orelli	Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool May 14, 2007 Brian Orelli	Little Product, Big Profits Abraxis Bioscience reports increased sales of its nano-sized drug. Investors, take note.